Treatment for Keratoconus
LaHaye Total Eye Care is proud to be among the first practices in Louisiana to perform an FDA-approved corneal collagen crosslinking procedure for the treatment of progressive Keratoconus.
In keratoconus, the cornea can become weak, thin, and unevenly shaped. Instead of keeping its normal round shape, corneas with keratoconus can protrude forward into the shape of a cone causing poor vision. Patients with keratoconus should not consider vision correction procedures like LASIK or PRK without undergoing extensive diagnostic testing.
Avedro is the first company to receive FDA approval for their KXL System that includes Avedro’s Photrexa Viscous and Photrexa, which are riboflavin solutions used with the KXL System during the procedure. Patients remain awake and comfortable during the cross-linking procedure, which is performed as an in-office procedure using ultraviolet light and a photosensitizer to strengthen chemical bonds in the cornea.
“The entire ophthalmic industry is extremely proud that the FDA has finally approved corneal collagen cross-linking for progressive keratoconus,” said Leon C. LaHaye, MD, founder and medical director of LaHaye Total Eye Care. “We are hopeful that as more eye doctors become aware of the debilitating disease that it will help in the early detection of patients with keratoconus.”
Corneal cross-linking has been proven to prevent further vision loss in over 95% of patients and increases vision in 60-81% of patients treated. Studies have also shown that corneal cross-linking can prevent the need for a corneal transplant and allows patients to wear contact lenses or glasses more comfortably and safely.
LaHaye Total Eye Care is proud to offer patients the benefits of the corneal collagen cross-linking procedure. If you have progressive keratoconus – or have questions about your vision – please contact us at 1-800-892-EYES to schedule an evaluation.